Latest Comments

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

Viability of GSK’s Mosquirix hinges on key pilot study for malaria prevention

AbbVie impresses with solid clinical data for its newest DAA regimen

AbbVie impresses with solid clinical data for its newest DAA regimen

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

FMT therapy from Rebiotix achieves positive Phase II results for recurrent C. difficile

Hope for sufferers with extremely rare form of liver cancer

Hope for sufferers with extremely rare form of liver cancer

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

AD/PD 2017 conference coverage: Future directions for Alzheimer's drug development

FOURIER outcomes data highlights the importance of value in drug development

FOURIER outcomes data highlights the importance of value in drug development

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

First-in-class opioid analgesic NKTR-181 boasts strong Phase III results

Aurinia poised to independently commercialise voclosporin in lupus nephritis

Aurinia poised to independently commercialise voclosporin in lupus nephritis

Positive results from the long-term extension of Nemolizumab in atopic dermatitis

Positive results from the long-term extension of Nemolizumab in atopic dermatitis

Results from IXORA-S show superiority of Taltz to Stelara in psoriasis

Results from IXORA-S show superiority of Taltz to Stelara in psoriasis

Tapinarof poised to fill a void in psoriasis treatment

Tapinarof poised to fill a void in psoriasis treatment

Results from phase IIb trial assessing tralokinumab for the treatment of atopic dermatitis

Results from phase IIb trial assessing tralokinumab for the treatment of atopic dermatitis

Primary results from phase IIb trial assessing olumacostat glasaretil for acne vulgaris

Primary results from phase IIb trial assessing olumacostat glasaretil for acne vulgaris

Eucrisa continues to show promise for the treatment of atopic dermatitis

Eucrisa continues to show promise for the treatment of atopic dermatitis

PARP inhibitor market in ovarian cancer set for a showdown

PARP inhibitor market in ovarian cancer set for a showdown

Minoryx’s MIN-102 secures orphan drug designation

Minoryx’s MIN-102 secures orphan drug designation

Competition is heating up in long-acting growth hormones for children

Competition is heating up in long-acting growth hormones for children

Promising preliminary data from Phase II study encourages Axovant to expand trial

Promising preliminary data from Phase II study encourages Axovant to expand trial

When faster is not better: the 'surrogate' example

When faster is not better: the 'surrogate' example

The importance of real world evidence in the 21st Century Cures Act

The importance of real world evidence in the 21st Century Cures Act

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis

Positive Phase IIb results position Synthetic Biologics’ Ribaxamase as serious contender for C. difficile Prophylaxis